Crafting precise multivalent architectures

Optimizing multivalency: Clusters of Man9 glycans, which are recognized by broadly neutralizing anti‐HIV antibody 2G12, have potential as HIV vaccines. However, optimal recognition by 2G12 requires optimum clustering of glycans. Using the recently described SELMA technique (SELection with Modified Aptamers), Man9 clusters have been developed, in which glycans are supported by DNA sequences selected from among 2×1013 variants (see scheme).

show abstract

“…[2] This concept has been extensively applied to the design of synthetic glycan clusters that bind to interesting biological targets. [3] …”

mentioning

confidence: 99%

Directed Evolution of 2G12‐Targeted Nonamannose Glycoclusters by SELMA

Temme

Drzyzga

Macpherson

et al. 2013

Chemistry A European J

View full text Add to dashboard Cite

show abstract

“…Most of these considerations can be addressed by selecting proper molecular weights, structure and architecture of the polymers, and by appropriate selection of linkers and spacers to achieve maximum therapeutic outcomes [11]. The most widely used polymer scaffolds include linear polymers, dendrimers, dendronized polymers, polypeptides, and nanogels [12]. Among all the polymeric scaffolds, linear polymers with multiple pendent ligands were the first applied as multivalent polymeric drugs due to their flexibility and ease of controlling the ligand density and polymer chain length.…”

Section: Multivalency As Key Feature Of Polymeric Drugsmentioning

confidence: 99%

Polymeric drugs: Advances in the development of pharmacologically active polymers

Jing

Chen

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Synthetic polymers play a critical role in pharmaceutical discovery and development. Current research and applications of pharmaceutical polymers are mainly focused on their functions as excipients and inert carriers of other pharmacologically active agents. This review article surveys recent advances in alternative pharmaceutical use of polymers as pharmacologically active agents known as polymeric drugs. Emphasis is placed on the benefits of polymeric drugs that are associated with their macromolecular character and their ability to explore biologically relevant multivalency processes. We discuss the main therapeutic uses of polymeric drugs as sequestrants, antimicrobials, antivirals, and anticancer and anti-inflammatory agents.

show abstract

“…Multivalency is a very important consideration in the design of robust therapeutic agents . Many proteins derive their functionality from interactions between multimeric subunits.…”

Section: Applications Of Polymer‐protein Conjugatesmentioning

confidence: 99%

“Bio”‐Macromolecules: Polymer‐Protein Conjugates as Emerging Scaffolds for Therapeutics

Borchmann

Carberry

Weck

2013

Macromol. Rapid Commun.

Self Cite

View full text Add to dashboard Cite

Polymer-protein conjugates are biohybrid macromolecules derived from covalently connecting synthetic polymers with polypeptides. The resulting materials combine the properties of both worlds: chemists can engineer polymers to stabilize proteins, to add functionality, or to enhance activity; whereas biochemists can exploit the specificity and complexity that Nature has bestowed upon its macromolecules. This has led to a wealth of applications, particularly within the realm of biomedicine. Polymer-protein conjugation has expanded to include scaffolds for drug delivery, tissue engineering, and microbial inhibitors. This feature article reflects upon recent developments in the field and discusses the applications of these hybrids from a biomaterials standpoint.

show abstract

Crafting precise multivalent architectures

Abstract: Development of elaborate three-dimensional multivalent displays appended on natural or synthetic molecular scaffolds.

Cited by 38 publications

References 140 publications

Directed Evolution of 2G12‐Targeted Nonamannose Glycoclusters by SELMA

Directed Evolution of 2G12‐Targeted Nonamannose Glycoclusters by SELMA

Polymeric drugs: Advances in the development of pharmacologically active polymers

“Bio”‐Macromolecules: Polymer‐Protein Conjugates as Emerging Scaffolds for Therapeutics

Contact Info

Product

Resources

About